Nellix takes $6M to treat aneurysms before they happen
Nellix Endovascular, a Palo Alto, Calif.-based maker of devices used to repair damaged blood vessels that could lead to aneurysms, has raised $6 million in debt, rights and securities, according to a filing with the SEC. Its backers include Essex Woodlands Health Ventures and Incept.
Complete Genomics seals $45M for cheaper gene sequencing
Complete Genomics, provider of supposedly cheaper and faster DNA sequencing services, has raised $45 million in a fourth round of funding — a huge amount for a biotech company in today’s economic environment. Based in Mountain View, Calif., the company says it will be able… Continue Reading
Oraya scores $42M for eye radiation treatments
Oraya Therapeutics, maker of radiosurgical tools used to treat eye diseases, has brought in $42 million in a third round of funding from Domain Associates, Scale Venture Partners, Essex Woodlands Health Ventures and Synergy Life Partners.
Based in Newark, Calif., the company says it will use… Continue Reading
Essex Woodlands raises almost $1B for life science investments
Essex Woodlands Health Ventures announced today that it brought in $900 million for its eighth fund, one of the largest sums ever raised by a health care-focused venture firm, according to the Wall Street Journal — even more impressive considering how the economic downturn has… Continue Reading
Neovista sees $18M to treat eye disorders
Neovista, a Fremont, Calif.-based biotech company specializing in eye diseases, says it raised $18 million in a fourth round of funding to commercialize its new device. The money came from Accuitive Medical Ventures, Carlyle Group, Essex Woodlands Health Ventures, MPM Capital, SV Life Sciences and… Continue Reading
Catalyst lands $40M to combat disease-causing proteins
Catalyst Biosciences has raked in $40.4 million in third-round funding to continue engineering an enzyme called protease to fight disease-causing proteins. The technology has the potential to affect many different diseases, including cancer and hemophilia. It has R&D agreements with Wyeth Pharmaceuticals and Centocor Research… Continue Reading
Medlogics to pump $30M into coronary stents
Santa Rosa, Calif. medical developer Medlogics has announced a $30 million fourth-round of funding from UBS AG that will close in the first quarter of 2009. The money will go toward marketing its new bare-metal stent, a device that props open blocked arteries, as well… Continue Reading
BioLogix bags $6M for oncology drug, names new CEO
Biopharm company BioLogix raised $6 million in first-round equity and debt financing from Essex Woodlands Health Ventures and New Science Ventures. The money will be used to continue development of its top cancer-fighting compound, but a second round is already in the works.
So far the… Continue Reading
Xanodyne newest pharm co. to cancel IPO
Xanodyne joins a growing number of biopharmaceutical and life science companies calling it quits on going public, at least for now. The Newport, Ky.-based firm withdrew its filing on Friday, citing poor market conditions — it had been waiting since November. Not that the company is… Continue Reading
Proteus snaps up $30M to take on heart failure
Proteus Biomedical Inc., a company developing microscopic electromechanical devices capable of one day treating or preventing congestive heart failure, brought in more than $30 million in its first call for fourth round financing. It’s original goal was $28.6 million, but CEO Andrew Thompson says the… Continue Reading
ReVance, topical botox company, raises $8M more
ReVance Therapeutics, a Mountain View, Calif biopharma company focused on topical botox, has raised $8 million more in financing.
Backers include executives of the company, Niagra Gorge Venture Partners, Biotechnology Development Fund, Essex Woodlands Health Ventures, Technology Partners Fund and Medics Pharma Corp.
It is the second… Continue Reading
Nellix raises $6.5M for aneurysm grafts
Nellix Endovascular, a Palo Alto, Calif., medical-device maker, raised $6.5 million in a third funding round, I’ve learned. The startup is developing a new treatment for repairing blood-vessel flaws in the chest and abdomen.
Those flaws, known as aneurysms, are thin-walled “bubbles” in blood vessels that… Continue Reading
Secretive Oraya raises more funds for eye devices
Oraya, a secretive Menlo Park, Calif., medical-device startup, has struck again. The company raised $18 million in what is presumably a second funding round, VentureWire reports (subscription required). Investors included Synergy Life Science Partners (see yesterday’s coverage of this newish VC firm here) and Essex… Continue Reading
Life sciences briefing: Thursday, Sept. 27, 2007
Featured companies: AstraZeneca, Atlantis Components, Cara Therapeutics, CardioMems, Corium International, New Ortho Polymers, Osprey Pharmaceuticals, Othera Pharmaceuticals, StrataGent Life Sciences
Corium acquires Stratagent, raises $25.1M for “transdermal” drugs — Corium International, a Menlo Park, Calif., biotech focused on drugs that can be delivered through the skin, said… Continue Reading
Horizon Therapeutics: Combining generic pain meds for greater drug safety
Palo Alto, Calif.-based Horizon Therapeutics, a biotech that aims to combine existing generic drugs to fight pain, raised $30 million in a third funding round. The company’s lead drug candidate, known only as HZT-501, is a “proprietary” combination of the generic drugs ibuprofen and famotidine,… Continue Reading
Stealthy Oraya raises $4M for medical devices
(UPDATED: See below.)
Oraya Therapeutics, a stealthy medical-device developer in Menlo Park, Calif., raised $4 million in a first funding round, VentureWire reports (subscription required). Essex Woodlands Health Ventures provided the funds.
From the VentureWire story:
Based in Menlo Park, Calif., Oraya is a stealth-mode medical device company founded… Continue Reading
StrataGent closes $16M round for needle-free injections
StrataGent Life Sciences, a San Jose developer of needle-free “microjet” injection systems, said it closed a $16 million second round of financing. The company has so far received $6.65 million of that round; the remainder should become available next year if and when StrataGent meets… Continue Reading
NeoVista, a co. targeting age-related macular degeneration, raises $41M
NeoVista, a Fremont ophthalmic device company focusing on the treatment of wet age-related macular degeneration, said it has raised a third $41 million round of venture financing.
The company is in the early stages of testing its technology, and it won’t hit the market until around… Continue Reading
Thermage, the anti-wrinkle company, suffers IPO bumbs — prices below forecast
Thermage, the Hayward maker of devices to treat wrinkles, priced six million common shares in its IPO at $7 per share, to raise $42 million.
It had originally wanted to raise $86 million, but lowered its pricing plans, first to between $11 and $13, but later… Continue Reading